Related Experiment Video
Updated: Jun 12, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Exceptional long term response to crizotinib in ROS 1-postive advanced non small cell lung cancer
Anjali Murali1, Anju Farsana A1, Sobha Subramaniam2
1Department of Medical Oncology, Amrita Institute of Medical Science and Research Centre Amrita Vishwa Vidyapeetham Kochi India.
Abstract:
Non-small-cell lung cancer (NSCLC) accounts for the majority of lung cancer cases worldwide, with a significant proportion of patients harbouring actionable oncogenic alterations. Among these alterations, the ROS1 rearrangement represents a distinct subset with therapeutic implications. Here, we present the case of a 52-year-old man diagnosed with advanced NSCLC harbouring the ROS1 fusion gene. Despite the initial poor response to conventional chemotherapy, the patient exhibited an exceptional and sustained response to crizotinib, with a progression-free survival of 94 months and complete metabolic response on PET scan. This case underscores the importance of molecular profiling in guiding treatment decisions and highlights the efficacy of targeted therapies for ROS1-positive NSCLC.
Insights
This case study shows a patient with advanced Non-small-cell lung cancer (NSCLC) who had a remarkable response to crizotinib, a targeted therapy for ROS1-positive NSCLC, lasting over 94 months.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer globally.
- A subset of NSCLC patients present with actionable oncogenic alterations, including ROS1 rearrangements.
- Identifying these alterations is crucial for effective treatment strategies.
Observation:
- A 52-year-old male patient with advanced NSCLC was diagnosed with a ROS1 fusion gene.
- Initial treatment with conventional chemotherapy yielded a poor response.
- The patient subsequently received crizotinib, a targeted therapy.
Findings:
- The patient demonstrated an exceptional and durable response to crizotinib.
- Progression-free survival exceeded 94 months.
- A complete metabolic response was confirmed by PET scan.
Implications:
- This case highlights the critical role of molecular profiling in NSCLC treatment selection.
- Targeted therapy with crizotinib is highly effective in ROS1-positive NSCLC patients.
- Long-term outcomes are achievable with personalized medicine approaches.
More Related Videos
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
